ArticleFrontiers in pharmacology2026
Exploring the mechanism of baicalein on choroid melanoma based on network pharmacology, transcriptomics and experimental verification.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Baicalein (BAI), a flavonoid from Scutellaria baicalensis, exhibits therapeutic potential across inflammation, viral infections, and cancers. Yet, its role in choroidal melanoma (CM), the most common intraocular malignancy, remains poorly understood. The aim of this study was to investigate BAI's anti-CM effects and underlying mechanisms by integrating network pharmacology, transcriptomic analyses, and experimental validation. Methods: Network pharmacology, molecular docking and transcriptomic analysis were used to identify potential targets and signaling pathways. The anti-tumor effect of baicalein was verified through combined intracellular and extracellular experiments. Western blotting was used to analyse the effects of BAI and IGF-1 co-treatment on the phosphorylation level of the pathway and its downstream cycling, apoptosis and migration related proteins. Results: Integrated analyses implicated the inhibitory effect of BAI on choroidal melanoma may be related to the cell cycle, apoptosis and critical signaling pathways, particularly the PI3K/AKT/mTOR axis. Conclusion: Our study demonstrates for the first time that BAI can inhibit CM malignant progression by modulating the PI3K/AKT/mTOR signaling pathway. This study suggests that BAI may be used as a promising anti-tumor agent for further treatment of CM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.